The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
BUSINESS
JCR to Fuel Licensing of J-Brain Cargo, Invest in Global R&D: President
JCR Pharmaceuticals is resolved to accelerate the licensing of its proprietary J-Brain Cargo blood-brain barrier (BBB)-penetrating technology in and outside Japan, Chairman and President Shin Ashida said at a press briefing on April 7. At the briefing held at a…
To read the full story
BUSINESS
- Enhertu Entering New Phase of Growth with Early-Line Breast Cancer Data: CEO
June 4, 2025
- Sawai Cuts FY2024 Results after Remitch Ruling, Net Profit Drops by Half
June 4, 2025
- Dupixent’s COPD Use Expected to Benefit Patients with Allergic Symptoms: Professor
June 3, 2025
- Kaken to Codevelop TWOCELLS’ Cell Therapy in Japan
June 3, 2025
- Taiho Out-Licenses LSD1 Inhibitor to Yokohama Upstart
June 3, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…